When to discontinue treatment of prolactinoma?

被引：16

作者：

Wass, JAH

机构：

[1] Univ Oxford, Oxford OX1 2JD, England

[2] Oxford Ctr Diabet Endocrinol & Metab, Dept Endocrinol, Oxford, England

来源：

NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM | 2006年 / 2卷 / 06期

关键词：

D O I：

10.1038/ncpendmet0162

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Prolactinomas are the most common hormone-secreting pituitary tumors. Treatment with dopamine agonists can stabilize disease and recent evidence suggests that in many cases therapy can be subsequently withdrawn without relapse. This Viewpoint discusses the safety and efficacy of dopamine agonist withdrawal and the optimal timing of this approach.

引用

收藏

页码：298 / 299

页数：2

相关论文

共 8 条

[1] Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia [J].

Colao, A ;

Di Sarno, A ;

Cappabianca, P ;

Di Somma, C ;

Pivonello, R ;

Lombardi, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :2023-2033

[2] The prevalence of pituitary adenomas - A systematic review [J].

Ezzat, S ;

Asa, SL ;

Couldwell, WT ;

Barr, CE ;

Dodge, WE ;

Vance, ML ;

McCutcheon, IE .

CANCER, 2004, 101 (03) :613-619

[3] NECROTIC CHANGES IN PROLACTINOMAS AFTER LONG-TERM ADMINISTRATION OF BROMOCRIPTINE [J].

GEN, M ;

UOZUMI, T ;

OHTA, M ;

ITO, A ;

KAJIWARA, H ;

MORI, S .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1984, 59 (03) :463-470

[4]

JOHNSTON DG, 1984, LANCET, V2, P187

[5] The effect of the menopause on prolactin levels in patients with hyperprolactinaemia [J].

Karunakaran, S ;

Page, RCL ;

Wass, JAH .

CLINICAL ENDOCRINOLOGY, 2001, 54 (03) :295-300

[6] CEREBROSPINAL-FLUID RHINORRHEA DURING TREATMENT WITH BROMOCRIPTINE FOR PROLACTINOMA [J].

KOK, JG ;

BARTELINK, AKM ;

SCHULTE, BPM ;

SMALS, A ;

PIETERS, G ;

MEYER, E ;

MERX, H .

NEUROLOGY, 1985, 35 (08) :1193-1195

[7] Dopamine resistance of prolactinomas [J].

Mark E. Molitch .

Pituitary, 2003, 6 (1) :19-27

[8] Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine [J].

Orrego J.J. ;

Chandler W.F. ;

Barkan A.L. .

Pituitary, 2000, 3 (3) :189-192